The Medicines and Healthcare Products Regulatory Agency of the United Kingdom (UK-MHRA) has reinstated full GMP status for Indoco Remedies’ Goa Plant I. This is an outcome of the full GMP inspection conducted by the MHRA from May 21- 23, 2019.
MHRA had inspected the Goa Plant I in March 2018, which resulted in issuance of a restricted GMP certificate for medicinally critical products and a statement of non- compliance was published in the EUDRAGMDP data base. Subsequently UK-MHRA conducted a 'Focused Audit' in October 2018 and GMP audit in May 2019. These audits were completed with no Critical Observations and Indoco has now received a full GMP status for its Goa Plant I.
Indoco Remedies is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs) in India.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1525.00 |
Dr. Reddys Lab | 5942.65 |
Cipla | 1345.35 |
Zydus Lifesciences | 925.95 |
Lupin | 1547.05 |
View more.. |